Incyte
INCY
#1208
Rank
NZ$32.54 B
Marketcap
NZ$162.93
Share price
-0.13%
Change (1 day)
51.44%
Change (1 year)

P/E ratio for Incyte (INCY)

P/E ratio as of May 2026 (TTM): 13.0

According to Incyte's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 13.0397. At the end of 2025 the company had a P/E ratio of 15.0.

P/E ratio history for Incyte from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202515.0-93.28%
2024223847.43%
202323.5-54.91%
202252.2204.83%
202117.1-127.34%
2020-62.6-249.06%
201942.0-65.67%
2018122-301.43%
2017-60.7-133.91%
2016179-96.7%
2015> 1000-2325.07%
2014-244159.92%
2013-93.8103.21%
2012-46.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Novartis
NVS
21.2 62.94%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.3 48.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
35.0 168.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
22.4 71.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Ligand Pharmaceuticals
LGND
33.0 153.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
-9.46-172.56%๐Ÿ‡บ๐Ÿ‡ธ USA
CTI BioPharma
CTIC
-15.7-220.19%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-17.9-236.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Ardelyx
ARDX
-26.6-303.73%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.